Stryker Corporation / MAKO Surgical Corp.

Knee and Hip Osteoarthritis (Robotic Orthopedic Surgery)

481K US cases/yr

Disease Overview

Osteoarthritis-driven knee and hip degeneration drives roughly half a million primary total knee arthroplasties annually in the US, with volumes projected to rise sharply as the population ages. Robotic-arm-assisted surgery aims to improve implant alignment, soft-tissue balance, and reproducibility versus manual instrumentation, particularly for partial knee resurfacing.

Competitive Landscape

Heading into the 2013 deal, the orthopedic recon market was dominated by five players: Zimmer, DePuy Synthes (J&J), Stryker, Smith & Nephew, and Biomet — competing on implant systems (e.g., Zimmer Persona, DePuy Attune, Stryker Triathlon) and surgeon relationships. Robotics was nascent: MAKO's RIO system plus RESTORIS implants drove ~$103M in 2012 sales as the clear segment leader, with competitors limited to Blue Belt's Navio (handheld, later acquired by Smith & Nephew), Curexo's ROBODOC, and OMNIlife's OMNIBotics — none with MAKO's installed base or partial-knee data. The deal mattered because Stryker paid an 86% premium (10.6x EV/sales vs. ortho-acquisition average of 3.1x) to lock up the leading robotic platform before Zimmer or DePuy could respond, and explicitly planned to port Stryker's Triathlon knee onto the RIO platform — converting MAKO from a single-implant ecosystem into a Stryker-implant pull-through engine. With <2% global surgical robotics penetration, the move was framed by Wells Fargo's Larry Biegelsen as a defensive lock-up of a differentiated platform that ultimately reshaped competitor robotics strategy (Zimmer/Rosa, J&J/Velys).